News summary
[Bailitianheng: "BL-B01D1 + PD-1 monoclonal antibody ± chemotherapy" obtained approval notice for drug clinical trials] Securities Times e Company News, Bailitianheng (688506) announced on the evening of May 6 that the company independently developedjokingapartvideopokerCombination of innovative biopharmaceutical injection BL-B01D1 (EGFR× HER3-ADC)jokingapartvideopoker...
Newsletter text
[Baili Tianheng: "BL-B01D1 + PD-1 Monoclonal Antibody ± Chemotherapy" Obtained Approval Notice for Drug Clinical Trial] Securities Times e Company News, Baili Tianheng (688506) announced on the evening of May 6 that the company's independently developed innovative biopharmaceutical injection BL-B01D1 The combination drug "BL-B01D1 + PD-1 monoclonal antibody ± chemotherapy" related to (EGFR× HER3-ADC) recently received 7 "Drug Clinical Trial Approval Notices" officially approved and issued by the State Food and Drug Administration (NMPA). Agree to carry out clinical trials of this product in combination with PD-1 monoclonal antibody ± chemotherapy for "advanced gastric cancer","advanced small cell lung cancer","advanced triple negative breast cancer","advanced urothelial cancer","advanced esophageal squamous cell carcinoma","advanced head and neck squamous cell carcinoma" and "advanced nasopharyngeal carcinoma".
